Public T-Cell Receptors (TCRs) Revisited by Analysis of the Magnitude of Identical and Highly-Similar TCRs in Virus-Specific T-Cell Repertoires of Healthy Individuals

Autor: Wesley Huisman, Lois Hageman, Didier A. T. Leboux, Alexandra Khmelevskaya, Grigory A. Efimov, Marthe C. J. Roex, Derk Amsen, J. H. Frederik Falkenburg, Inge Jedema

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Since multiple different T-cell receptor (TCR) sequences can bind to the same peptide-MHC combination and the number of TCR-sequences that can theoretically be generated even exceeds the number of T cells in a human body, the likelihood that many pub

Externí odkaz: https://doaj.org/article/8c317c5f5ec342cead55f08d7667e8af

Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells Is Dictated by HLA-Restriction

Autor: Wesley Huisman, Didier A. T. Leboux, Lieve E. van der Maarel, Lois Hageman, Derk Amsen, J. H. Frederik Falkenburg, Inge Jedema

Publikováno v: Frontiers in Immunology, Vol 12 (2021)

T-cell products derived from third-party donors are clinically applied, but harbor the risk of off-target toxicity via induction of allo-HLA cross-reactivity directed against mismatched alleles. We used third-party donor-derived virus-specific T cell

Externí odkaz: https://doaj.org/article/98f2725cc9f64cd1bfd462fb0ce03440

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Autor: Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen

Publikováno v: New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125

Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485a
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292

Data from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

Autor: Mirjam H.M. Heemskerk, J.H. Frederik Falkenburg, Peter A. van Veelen, Marieke Griffioen, Inge Jedema, Pieter S. Hiemstra, Cees van Kooten, Gert-Jan Lugthart, Arnoud H. de Ru, Michel D.G. Kester, Renate de Boer, Renate S. Hagedoorn, Marleen M. van Loenen, Dirk M. van der Steen, Avital L. Amir

Purpose: In human leukocyte antigen (HLA)–matched stem cell transplantation (SCT), it has been shown that beneficial immune response mediating graft-versus-tumor (GVT) responses can be separated from graft-versus-host disease (GVHD) immune response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36cf24e0108815942b715fa879613def
https://doi.org/10.1158/1078-0432.c.6519483.v1

Supplementary Methods, Figure Legends 1-3 from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

Autor: Mirjam H.M. Heemskerk, J.H. Frederik Falkenburg, Peter A. van Veelen, Marieke Griffioen, Inge Jedema, Pieter S. Hiemstra, Cees van Kooten, Gert-Jan Lugthart, Arnoud H. de Ru, Michel D.G. Kester, Renate de Boer, Renate S. Hagedoorn, Marleen M. van Loenen, Dirk M. van der Steen, Avital L. Amir

PDF file - 77K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::433dec174abe8cc4440866f35065105e
https://doi.org/10.1158/1078-0432.22442826